P‑32 (phosphorus‑32) is a radioactive isotope used to treat certain blood disorders—primarily polycythaemia vera and other myeloproliferative diseases—by suppressing overactive bone marrow to reduce high red‑cell or platelet counts. It has also been used historically for some malignant effusions and refractory joint synovitis, though its use has declined with newer targeted therapies and safety considerations.

P‑32 (phosphorus‑32) is a radioactive beta‑emitting isotope used as targeted radiotherapy. It’s usually injected directly into body cavities (e.g., pleural or peritoneal malignant effusions) or lesions so beta particles destroy nearby tumor cells with limited penetration. Risks include local inflammation, pain and bone‑marrow suppression; pregnancy and breastfeeding are contraindications. Treatment requires radiation‑safety measures and blood‑count monitoring for hematologic toxicity.

Phosphorus‑32 provides targeted beta radiation useful therapeutically and diagnostically. Clinically it treats myeloproliferative disorders (e.g., polycythemia vera) by suppressing overactive bone marrow and lowering blood counts, relieves pain from bone metastases, and can control malignant effusions when instilled intraperitoneally. It’s also valuable as a research tracer and radiolabel for studying biochemical and cellular processes.

P-32 (phosphorus‑32) is a radioactive isotope that emits high‑energy beta particles and has a half‑life of about 14.3 days. It’s used in medicine for targeted internal therapies and in laboratories as a tracer. Beta radiation penetrates only a few millimeters of tissue but is an internal hazard if ingested or inhaled. Handling requires shielding, contamination control, and radiation monitoring.

Yes. Intravenous sodium phosphate can cause gastrointestinal side effects, including diarrhea, abdominal cramps, and nausea. Diarrhea is more commonly seen with oral phosphate bowel preparations but may occur with IV therapy due to electrolyte and fluid shifts. Monitor for worsening diarrhea, dehydration, or signs of electrolyte imbalance (muscle cramps, weakness) and inform your healthcare provider promptly.

Phosphorus-32 (P-32) has a physical half-life of about 14.3 days (≈343 hours), during which its activity falls by half. It decays by beta emission (maximum beta energy ≈1.71 MeV). For decay calculations use A(t) = A0·(1/2)^(t/14.3 d) or λ = ln2 / 14.3 d. Because of this relatively short half-life, P-32 is used for temporary medical and research labeling.